By Coco Jervis and Sue Perez Negligible Increases for AIDS, TB, Viral Hepatitis Treatment and Research On Monday, February 1, 2010, President Barack Obama unveiled his fiscal year (FY) 2011 budget to the U.S. Congress. Global health programs were allocated…
By Tracy Swan and Lei Chou Background: In the United States, the highest all-cause mortality rates are found among African American men and women aged 25 to 64. This racial disparity is underscored by a disproportionate burden of viral hepatitis…
by Coco Jervis Cuba boasts model health outcomes but at what costs to human rights? In November 2009 TAG’s senior policy associate, Coco Jervis, attended the Global Forum for Health Research meeting in Havana, Cuba, under a special license that…
By Javid Syed BOTUSA study strongly supports continuous preventive IPT for people with HIV Tuberculosis (TB) remains the leading cause of death among people living with HIV. The World Health Organization’s 2009 report Global Tuberculosis Control: Epidemiology, Strategy, Financing reported…
By Claire Wingfield After 40 years of scientific stagnation, it is beginning to be an exciting time in tuberculosis treatment research. Tuberculosis (TB) is the leading killer of people with HIV worldwide, accounting for more than quarter of all HIV…
By Richard Jefferys On Friday, January 15, the National Institutes of Allergy & Infectious Diseases (NIAID) sponsored a scientific workshop entitled “The Next Challenge: Elimination of HIV Reservoirs.” The event took place during the Keystone conference on HIV pathogenesis in…
By Mark Harrington Safer and more effective drug combinations included in new guidelines... Unusually, there was something to celebrate on World AIDS Day in 2009, even if it was only on paper. The World Health Organization (WHO) updated its antiretroviral…
On October 25, 2010, the nonprofit microbicide research organization CONRAD announced that the U.S. Food and Drug Administration (FDA) would consider the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial as a confirmatory trial to the CAPRISA 004…
By Coco Jervis Big changes are planned for the $300 million AIDS clinical trials networks funded by the U.S. National Institutes of Health (NIH). Founded in 1987 at the height of the AIDS crisis, the networks are credited with numerous…
By Claire Wingfield After nearly 50 years, there is finally something to get excited about in tuberculosis (TB) drug development. Tibotec’s TMC207—the first compound from a novel class of TB drugs, the diarylquinolines—will likely be submitted to the U.S. Food…